HMNC Holding GmbH
- Address
- Wilhelm-Wagenfeld-Strasse 20, Schwabing-Freimann
Sponsor Overview
Specializations
Psychiatry and Mood Disorders
HMNC Holding GmbH focuses on Major Depressive Disorder, with clinical research centred on depressive symptom management in outpatient settings and the evaluation of targeted approaches for patients with specific biological profiles.
- Major Depressive Disorder
- Depressive symptoms
- Outpatient psychiatry
The sponsor’s research activity is concentrated in mood disorder treatment, with interest in patient subgroups defined by polygenic risk markers and related neurobiological characteristics.
Biomarker-Driven Therapeutic Research
Clinical work supported by the sponsor includes investigation of genetically informed patient selection, particularly in relation to V1b receptor-associated biology and subgroup-specific treatment response in depression.
- Polygenic score-based stratification
- V1b receptor biology
- Precision psychiatry
This area reflects a therapeutic interest in linking biological markers with antidepressant response in psychiatric disorders.
Antidepressant Development
The sponsor is involved in the clinical evaluation of BH-200 for depression, with attention to its role in improving clinical outcomes in adults living with Major Depressive Disorder.
- Antidepressant therapy
- Clinical efficacy
- Tolerability
Research activity is directed toward pharmacological treatment options for mood regulation and symptom relief in psychiatric care.
Multicentre International Clinical Research
HMNC Holding GmbH supports a geographically distributed research network across multiple countries and collaborating sites, enabling clinical investigation in mental health populations within routine outpatient contexts.
- Multinational trial activity
- Collaborating research sites
- Outpatient study populations
The sponsor’s clinical footprint is centred on European pharmaceutical research with active involvement in psychiatric drug development.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Tolerability of BH-200 (Nelivaptan) in V1b-High Outpatients with Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase II Study |  Bulgaria Estonia Germany Lithuania Poland Slovakia Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 43 sites across their trial portfolio.
Therapeutic Focus
- 1.Mental Disorders1 trial150 other sponsors
Partnered Research Centres
43 centres- Address
- Bulevard Vasil Aprilov 9, 4002 Plovdiv
- Address
- Bernolakova 24, 953 01 Zlate Moravce
- Address
- Complex Lazur, Lake Park, 8001 Burgas
- Address
- Bulevard Tutrakan 20, 7003 Rousse
- Address
- Belasita Str 1, 3000 Vratsa
- Address
- Ul. 28 Czerwca 1956 R. 194, 61-485 Poznan
Want to get in touch with this sponsor?
Send a question and we'll pass it on to HMNC Holding GmbH.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.